The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL)

Leukemia Research

Volumn 32, Issue 12, 2008, Pages 1815-1819

  Giannopoulos, K ^a,b   Schmitt, M ^b   Kowal, M ^a   Wlasiuk P ^a   Bojarska Junak, A ^a   Rolinski J ^a   Dmoszynska A ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

B cell chronic lymphocytic leukemia (B CLL); Human leukocyte antigen G (HLA G); Soluble HLA G (sHLA G)

Indexed keywords

CD38 ANTIGEN; HLA G ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; DNA PRIMERS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; SEQUENCE DELETION;

EID: 51649086859     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.04.008     Document Type: Article

References (21)

1. Keating M.J., Chiorazzi N., Messmer B., Damle R.N., Allen S.L., Rai K.R., et al. Biology and treatment of chronic lymphocytic leukemia. Hematol ASH Educ Prog (2003) 153-175
2. Hamblin T.J. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 20 (2007) 455-468
3. Montserrat E. New prognostic markers in CLL. Hematol ASH Educ Prog (2006) 279-284
4. Zenz T., Döhner H., and Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20 (2007) 439-453
5. Rebmann V., Nuckel H., Duhrsen U., and Grosse-Wilde H. HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications. Semin Cancer Biol 17 (2007) 430-435
6. Nuckel H., Rebmann V., Durig J., Duhrsen U., and Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105 (2005) 1694-1698
7. Rouas-Freiss N., Moreau P., Menier C., and Carosella E.D. HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol 13 (2003) 325-336
8. Giannopoulos K., Dmoszyńska A., Bojarska-Junak A., Roliński J., and Schmitt M. Expression of HLA-G in patients with early stages of B-cell chronic lymphocytic leukemia (B-CLL). Pol. J. Environ Stud 15 (2006) 37-40
9. Dal Porto J., Johansen T.E., Catipović B., Parfiit D.J., Tuveson D., Gether U., et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA 90 (1993) 6671-6675
10. Fournel S., Aguerre-Girr M., Huc X., Lenfant F., Alam A., Toubert A., et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol. 164 (2000) 6100-6104
11. Giannopoulos K, Dmoszyńska A, Bojarska-Junak A, Schmitt M, Roliński J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol; in press.
12. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
13. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig. V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999) 1840-1847
14. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
15. Bojarska-Junak A., Giannopoulos K., Kowal M., Dmoszynska A., and Rolinski J. Comparison of methods for determining zeta-chain associated protein-70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). Cytometry B Clin Cytom 70 (2006) 293-301
16. Polakova K., Krcova M., Kuba D., and Russ G. Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res 27 (2003) 643-648
17. Amiot L., Le Friec G., Sebti Y., Drénou B., Pangault C., Guilloux V., et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 13 (2003) 379-385
18. Rezvany M.R., Kazemi A., Hajifathali A., Kaviani S., and Mellstedt H. Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. Iran Biomed J 11 (2007) 125-129
19. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia; in press.
20. Perez-Chacon G, Rosado S, Rebolleda N, Losada-Fernandez I, Vargas JA, Morado M, Jorda J, Perez-Aciego P. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int J Lab Hematol; in press.
21. Stahlhut Espinosa C.E., and Slack F.J. The role of microRNAs in cancer. Yale J Biol Med 79 (2006) 131-140